Cyclophosphamide/dexamethasone/etoposideTumour lysis syndrome and lack of efficacy: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1912卷 / 1期

关键词：

D O I：

10.1007/s40278-022-17868-9

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：165 / 165

相关论文

共 50 条

[1] EtoposideTumour lysis syndrome: case report
Reactions Weekly, 2016, 1629 (1) : 111 - 111
[2] EtoposideTumour lysis syndrome: case report
Reactions Weekly, 2022, 1903 (1) : 180 - 180
[3] Carboplatin/etoposideTumour lysis syndrome: case report
Reactions Weekly, 2022, 1907 (1) : 127 - 127
[4] Carboplatin/etoposideTumour lysis syndrome: case report
Reactions Weekly, 2014, 1523 (1) : 51 - 51
[5] Cisplatin/etoposideTumour lysis syndrome: case report
Reactions Weekly, 2007, 1168 (1) : 11 - 11
[6] Cyclophosphamide/dexamethasone/vincristineTumour lysis syndrome: case report
Reactions Weekly, 2009, 1257 (1) : 16 - 16
[7] Bleomycin/cisplatin/etoposideTumour lysis syndrome: case report
Reactions Weekly, 2022, 1895 (1) : 102 - 102
[8] AntineoplasticsTumor lysis syndrome and lack of efficacy: case report
Reactions Weekly, 2022, 1937 (1) : 69 - 69
[9] AntineoplasticsTumor lysis syndrome and lack of efficacy: case report
Reactions Weekly, 2023, 1938 (1) : 172 - 172
[10] AntineoplasticsTumour lysis syndrome and lack of efficacy: case report
Reactions Weekly, 2022, 1935 (1) : 76 - 76

← 1 2 3 4 5 →